EVEROLIMUS

EVEROLIMUS

Application

Everolimus has been used as an mechanistic target of rapamycin complex 1 (mTORC1) inhibitor to study its effect on MCF7 and MDA-MB-231 cell lines.

Biochem/physiol Actions

Everolimus, the 40-O-(2-hydroxyethyl) derivative of rapamycin (sirolimus), is a potent and selective inhibitor of mechanistic target of rapamycin (mTOR). Everolimus is selective for the mTORC1 protein complex. Everolimus exhibit potent immunosuppressive and anticancer activities.

Everolimus, a substrate for P-glycoprotein (P-gp) can be used to treat advanced neuroendocrine tumors (NETs).

No detailed specifications are available for this product.

There are no downloads for this product.

Code Description Colour InChI key InChI Manufacturer Form Assay Price Quantity
3576083 EVEROLIMUS white to beige HKVAMNSJSFKALM-GKUWKFKPSA-N 1S/C53H83NO14/c1-32-16-12-11-13-17-33(2)44(63-8)30-40-21-19-38(7)53(62,68-40)50(59)51(60)54-23-15-14-18-41(54)52(61)67-45(35(4)28-39-20-22-43(66-25-24-55)46(29 SIGMA-ALDRICH
£156.00 (exc VAT) per 10MG
-
+
3576084 EVEROLIMUS white to beige HKVAMNSJSFKALM-GKUWKFKPSA-N 1S/C53H83NO14/c1-32-16-12-11-13-17-33(2)44(63-8)30-40-21-19-38(7)53(62,68-40)50(59)51(60)54-23-15-14-18-41(54)52(61)67-45(35(4)28-39-20-22-43(66-25-24-55)46(29 SIGMA-ALDRICH
£626.79 (exc VAT) per 50MG
-
+